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Objective: Postoperative anemia and multiple blood transfusions are still important
problems in cardiac surgery. During the past few years, there have been some
reports indicating that multiple recombinant human erythropoietin infusions start-
ing at least 2 weeks before the operation induced erythropoiesis. We aimed to
reduce the risk of adverse reactions of high doses of recombinant human erythro-
poietin and reduce the period of hospitalization by using it only once, 4 days before
the operation.
Methods: Twenty-five patients received recombinant human erythropoietin 4 days
before the operation, and 28 patients comprised the control group. All the hemato-
logic parameters of the patients are measured on the day of admission, the day
before the operation (fourth day), the first day after the operation, and 1 week later.
Results: In the recombinant human erythropoietin group the mean hemoglobin con-
centration increased on the morning of the operation (14.5 ± 0.52 g/dL in the
recombinant human erythropoietin group and 12.4 ± 0.65 in the control group, P <
.05). To maintain hemoglobin levels at greater than 8.5 g/dL, 330 ± 33 mL of
homologous transfusion was required in the recombinant human erythropoietin
group, whereas 680 ± 75 mL was required in the control group (P < .01).
Conclusion: Recombinant human erythropoietin induces erythropoiesis rapidly, even
when it is used with a low single dose just 4 days before the operation. No adverse reac-
tions were seen with this kind of recombinant human erythropoietin treatment.
Anemia is one of the main problems seen after cardiac surgery.Activation of the contact coagulation factors during extracorpore-al circulation causes activation of the complex fibrinolytic sys-tem.1-3 Studies have shown that there are major reductions in theplasma levels of almost all factors, but most of these changes arecaused by hemodilution.4,5 Moreover, cardiopulmonary bypass
(CPB) shortens the erythrocyte life by increasing its fragility.6-8 Because of the rea-
sons mentioned above and despite the meticulous surgical hemostasis, blood loss
can be so great as to cause anemia. For the treatment of this anemia, whole blood
and blood products are used, which also causes a lot of problems, such as transfu-
sion reactions, volume overload, and infections.9-11
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There are many reports on blood salvage methods,
diminishing blood loss, materials used instead of whole
blood, and drugs that induce erythropoiesis. Autologous
donation is the most preferred method to replace blood,
fresh platelets, and coagulation factors; however, anemia is
a common problem in cardiac surgery, even if autologous
transfusion was made.
In 1977, Miyake and colleagues12 isolated erythropoietin
(EPO) hormone, which induces erythropoiesis, and in 1985,
Jacob and colleagues13 produced recombinant human EPO
(r-Hu EPO) for the first time by using recombinant DNA
technology, and this has been a great development for the
treatment of the anemia caused by diminished erythro-
poiesis. At present, r-Hu EPO has become the main agent in
treating the anemia caused by reduced erythropoiesis, which
is seen in chronic renal insufficiency and some hematologic
diseases.14,15
In this study we aimed to investigate the effect of low-
and single-dose (100 IU/kg) r-Hu EPO on erythropoiesis by
using it 4 days before the operation.
Methods
This single-blind study included 53 patients who were randomly
chosen from those waiting for elective coronary artery bypass
grafting surgery between October 1999 and February 2000. Only
the nurse who had done the injections knew which patients
belonged to which group. All the patients were informed about the
study, informed consent was obtained, and institutional review
board approval was taken. Twenty-eight of the subjects formed the
control group. The remaining 25 patients received 100 IU/kg r-Hu
EPO intravenously 4 days before the operation (r-Hu EPO group).
Hemotologic system analysis of the patients was normal. Patients
in this study did not receive supplementary iron. None of these
patients had any disease or addiction (eg, drug abuse, alcohol
abuse, and corticosteroid treatment) that might possibly affect
bone marrow response. The mean time between the admission and
cardiac catherization was 11.3 ± 9 days (up to 64 days). None of
the patients were operated urgently. The characteristics of both
groups are shown in Table 1. There is no statistically significant
difference in the preoperative characteristics between the 2 groups.
The complete blood cell counts, routine serum chemical param-
eters, serum iron values, iron-binding capacity values, and serum
EPO levels were measured on admission, on the day before the
operation (4 days after admission), on the first postoperative day,
and 1 week after the operation. Complete blood cell counts were
performed with the Coulter STK 5 (Coulter Corporation, Hialeah,
Fla), and EPO levels were measured with an enzyme-linked
immunosorbent assay (Quantikine IVD catalog number DEP00).
The reticulocyte levels were measured by using the manual
method. All patients donated 400 mL of their own blood on the
morning of the operation. This blood was conserved and given
back to the patients after protamine administration. All patients
underwent successful coronary bypass surgery without major com-
plications. All operations were carried out with CPB with the
SciMed membrane oxygenator (SciMed/Boston Scientific
Corporation, Osseo, Minn), cold potassium cardioplegic solution,
and moderate hypothermia. During CPB, the hematocrit level was
maintained over 20%, and all the blood in the circuit was rein-
fused. One large-bored, silicone-coated thoracic drain was placed
in mediastinum, and thoracic cavities were drained separately if
required. Postoperative drainage was collected to an underwater
drainage system, and the shed blood was not reinfused. Patients’
lungs were ventilated with volume-controlled ventilators for at
least 4 hours (mean, 6 hours). A positive end-expiratory pressure
of 5 to 10 mm Hg was used unless hemodynamic instability was
present. In the postoperative period, hematocrit levels of the
patients were kept above 28% (8.5 g/dL hemoglobin) by adminis-
tration of blood.
All data were expressed as means ± standard deviation. The sta-
tistical evaluation of the results has been made according to the
Student t test and test for 2 proportions from independent groups.
Results
All patients underwent successful coronary bypass surgery
without major complications. None of the patients under-
went reoperation. They have completed their postoperative
course, and they were discharged on the eighth to eleventh
postoperative days.
On admission to the hospital, there was no significant
difference in hemoglobin values between the 2 groups (con-
trol group, 12.5 ± 0.51 g/dL; r-Hu EPO group, 12.1 ± 0.38
g/dL; P > .05). After r-Hu EPO administration, hemoglobin
values were elevated significantly (14.5 ± 0.52 g/dL) in the
r-Hu EPO group, and this finding was significantly different
from those in the control group (P < .05). Therefore, the pre-
operative hemoglobin values were higher in the r-Hu EPO
group than in the control group. The hemoglobin values
measured 24 hours after the operation were not significant-
ly different between the 2 groups (control group, 10.3 ± 0.60
g/dL; r-Hu EPO group, 11.2 ± 0.72 g/dL; P > .05). In our
intensive care unit, hemoglobin values of the patients were
measured every 3 hours in the first 24 hours after the oper-
ation, and the patients with lower hemoglobin values
received homologous blood transfusion. There is no signifi-
cant difference between the hemoglobin values of the 2
groups at the end of the first week (control group, 11.5 ±
0.58 g/dL; r-Hu EPO group, 12.1 ± 0.62 g/dL; P > .05).
In the r-Hu EPO group the patients received 330 ± 43 mL
of homologous blood transfusion from the time of operation
until discharge from the hospital. The control group
received 680 ± 75 mL of homologous blood during the same
period. The difference between the 2 groups was found to be
significant (P < .01).
There was no significant difference in the reticulocyte
values between both groups when they were admitted to the
hospital (control group, 55 ± 9.80/mm3; r-Hu EPO group,
51 ± 7.01/mm3; P > .05). The patients who received r-Hu
EPO had significantly higher reticulocyte values after the r-
HU EPO administration than those in the control group
(control group, 53 ± 8.20/mm3; r-Hu EPO group, 135 ±
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15.07/mm3; P < .01). Even though the reticulocyte values
increased slightly in the control group 24 hours after the
operation, the difference in these values between the 2
groups was found to be significant (control group, 68 ±
8.06/mm3; r-Hu EPO group, 126 ± 9.35/mm3; P < .01). At
the end of the first week, the reticulocyte values decreased
in the r-Hu EPO group, but they were still higher than
admission values, whereas they had increased slightly in the
control group. Therefore, no significant difference was
observed between the 2 groups at the end of the first week
(control group, 88 ± 9.99/mm3; r-Hu EPO group, 75 ±
10.35/mm3; P > .05), but these reticulocyte levels of both
groups were significantly higher than the hospitalization
levels (P < .05).
There was no statistically significant difference in the
serum EPO values between the 2 groups (P > .05). However,
the postoperative serum EPO values of the control group
were slightly higher than the preoperative values of the
same group, and this elevation was not statistically signifi-
cant (P > .05). The brevity of the elimination half-life of r-
Hu EPO (4 hours) did not cause any change in the serum
EPO levels of the patients.
All preoperative and postoperative serum iron and
iron-binding capacity values were not significantly differ-
ent between the 2 groups (P > .05). All data are shown in
Table 2.
During the first 24-hour period postoperatively, 470 ± 45
mL of drainage was observed in the control group, whereas
430 ± 40 mL of drainage was detected in the r-Hu EPO
group. There was no significant difference in the drainage
fluid values between the 2 groups (P > .05).
Discussion
Anemia is still one of the main problems seen after cardiac
surgery. Today, it is still controversial under which hemo-
globin value we should transfuse whole blood, blood prod-
ucts, or both. There are several authors who propose trans-
fusion under the hemoglobin values of 6 g/dL (this limit is
much lower in children), whereas others stated that transfu-
sion should be made to the patients with hemoglobin values
of 8.5 to 9.0 g/dL.16-19 Low hemoglobin values have great
effect on postoperative morbidity. For this reason, we do not
permit hemoglobin values under 8.5 g/dL in our patients.
Blood should be used in the prime solution before under-
going CPB for the patients who had anemia preoperatively,
so that extreme decreases in the hemoglobin values during
the CPB are prevented.
It was observed that the patients who received r-Hu EPO
had induced erythropoiesis in a short period of time and had
a marked increase in their hemoglobin values. The hemo-
globin value of the r-Hu EPO group was 12.1 ± 0.38 g/dL as
they were hospitalized and 4 days after r-Hu EPO adminis-
tration, and on the day of operation, the values increased to
14.5 ± 0.52 g/dL. The difference between these values
appeared to be statistically significant (P < .01). The hemo-
globin value of the control group was 12.4 ± 0.65 g/dL on
the day of the operation. The difference between the 2
groups’ hemoglobin values was statistically significant (P <
.05). Therefore, the patients in the r-Hu EPO group had
undergone the operations with higher hemoglobin values
than those in the control group. However, another study still
going on in our center showed that r-HU EPO treatment in
normal patients who had hemoglobin levels of more than
13.5 g/dL had no significant changes in 4 days.
During the period between the operation and the dis-
charge from the hospital, the patients in the r-Hu EPO group
received 330 ± 33 mL of homologous blood transfusion.
The patients in the control group were transfused with 680
± 75 mL of homologous blood during the same period. The
difference between the 2 groups was statistically significant
(P < .01). Therefore, it was observed that the requirement of
blood products for the EPO group is less than that for the
subjects in the control group.
Studies about r-Hu-EPO administration before cardiac
surgery have been reported in the literature.20-25 Moreover,
Watanabe and colleagues26 reported the administration of
the r-Hu EPO in the week after the operation in addition to
preoperative use. Also, there are reports about administra-
tion of r-Hu EPO in multiple doses. Kiyama and associ-
ates27 reported 3 weeks’ (once weekly) use of r-Hu EPO in
anemic patients before the cardiac operation, but this has the
disadvantage of overstay in the hospital. In all these studies,
hemoglobin values showed a marked increase, and the
requirement for blood and blood products markedly
decreased. Treatment with r-Hu EPO can result in hyperten-
sion, deep venous thrombosis, hypercalcemia, flulike syn-
drome, and headache-like side effects.28,29 These side
effects are usually seen in patients who undergo chronic r-
Hu EPO treatment. In our study we did not observe any
TABLE 1. Characteristics of patients
Control group r-Hu EPO group
No. of patients 28 25
Age (y)
Mean 56.2 ± 4.7 59.8 ± 5.4
Minimum 38 36
Maximum 77 80
Sex 
Male 17 16
Female 11 9
Weight (kg) 68.7 ± 9.2 70.3 ± 8.3
Mean hospitalization (d) 9.1 ± 0.6 9.7 ± 0.8
Crossclamp time (min) 51.2 ± 6.2 47.7 ± 5.9
Total operative time (min) 192.6 ± 11.4 211.6 ± 14.6
Revascularized coronary arteries (n) 2.7 ± 0.4 3.2 ± 0.5
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complications caused by administration of r-Hu EPO. We
think that single low-dose r-Hu EPO administration might
play a role in avoiding complications.
Blood and blood product transfusions may result in many
adverse effects, such as transfusion reactions, volume over-
loading, or infections. Also, unnecessary use of blood and
blood products should be avoided because they are difficult
to obtain, and it is also expensive to prepare them.
Therefore, we believe that by receiving a 100 IU/kg single
dose of r-Hu EPO less than 1 week (4 days) before the oper-
ation, patients will have higher hemoglobin values before
the operation, and the requirement of blood and blood prod-
ucts in the postoperative period will markedly decrease.
Doing this study in a double-blind, randomized fashion
would be more scientific, but high costs of hospitalizing a
nonsurgical patient forced us to do this study in the way
described here, and we think this is the main weakness of the
study. Because of this, we believe that subsequent studies
done with nonsurgical patients will provide more informa-
tion about this inexpensive blood conservation technique.
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